In a negative development for Lupin, USFDA has issued a combined warning letter for Lupin's Goa (oral solid) formulation plant and Pithampur (Indore) unit II (oral solid, ophthalmic) formulation plants. Although normal despatches from these two facilities will likely continue, any further new launches will be delayed until the resolution of the warning letter. Lupin's management expects resolution of this warning letter within 12-15 months. In the meantime, the management has identified at least 12 pending ANDAs (of total 45-50 pending ANDAs from these two...